ClinicaliQ Trial Snapshot
- Study of BHV-1400 in IgA Nephropathy — Recruiting • Phase I • NCT07054684.
- What is being tested: BHV-1400, a novel investigational treatment, is being evaluated for safety and tolerability in patients with IgA Nephropathy (IgAN), the most common primary glomerulonephritis globally.
- Patient eligibility overview: The trial enrolls participants with confirmed IgAN diagnosis; specific inclusion/exclusion criteria would determine baseline kidney function, disease stage, and prior treatment history eligibility requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility Snapshot
- Key Inclusion Criteria:
- Participants must have biopsy-confirmed IgA Nephropathy Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.